Showing 651-660 of 676 results for "".
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Dermatology Partnerships Exploredhttps://practicaldermatology.com/news/20121115-dermatology_partnerships_explored/2459681/Research and Markets has added the "Dermatology Partnering Terms and Agreements" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter dermatology
- Murad Names Fred Gysi Chief Financial Officerhttps://practicaldermatology.com/news/20121115-murad_names_fred_gysi_chief_financial_officer/2459682/Fred Gysi now serves as Chief Financial Officer for Murad. In this role, Gysi will be responsible for financial reporting, budgeting, treasury and cash flow management, financial and marketing analysis, and strategic planning. Gysi comes to Murad w
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- Medical Entrepreneur Symposium Adds Breakout Sessionhttps://practicaldermatology.com/news/20121024-medical_entrepreneur_symposium_adds_breakout_session/2459693/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers, and executives in healthcare, has added a breakout session for physician entrepreneurs wanting to take great business ideas or medical devices to market. Dr. Arlen Meyers will be the course direct
- Janssen Launches Online Resource for Healthcare Professionalshttps://practicaldermatology.com/news/20121002-janssen_launches_online_resource_for_healthcare_professionals/2459725/Janssen Scientific Affairs recently launched a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. JanssenMD (www.janssenmd.com) is a web-based application is designed for use on desktops, tablets,
- Galderma's Cetaphil Celebrates 65 Yearshttps://practicaldermatology.com/news/20120711-galdermas_cetaphil_celebarates_65_years/2459775/Galderma's Cetaphil Gentle Skin Cleanser is celebrating 65 years on the market. Introduced in 1947 as Cetaphil Cleansing Lotion, it was initially developed by a pharmacist for use as a compounding base. By the 1960s, the product was so popular t
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn